Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T18:09:09.522Z.
Calculation as of: 2026-10-06T18:09:09.522Z.
Quote observation: 2026-10-06T17:51:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: e7a98ef6549bf85b46c4ba181efc1584300b0c5a2a31302d891700dc780dc00a
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Pluri Inc.
Market Cap
$10.59M
EV/EBIT Ratio
N/A
| NAME | MARKET CAP | EV/EBIT RATIO |
|---|---|---|
| Pluri Inc. (PLUR) | $10.59M | N/A |
| Tvardi Therapeutics, Inc. (TVRD)vs › | $10.59M | N/A |
| Lisata Therapeutics, Inc. (LSTA)vs › | $10.56M | N/A |
| CytoMed Therapeutics Limited (GDTC)vs › | $10.51M | N/A |
| Satellos Bioscience Inc. (MSLE)vs › | $10.37M | N/A |
| Polyrizon Ltd. (PLRZ)vs › | $10.83M | N/A |
| Senti Biosciences, Inc. (SNTI)vs › | $10.31M | N/A |
| Lifeward Ltd. (LFWD)vs › | $10.26M | N/A |
| Adial Pharmaceuticals, Inc. (ADIL)vs › | $11.36M | N/A |
| Cerenome, Inc. (CNSY)vs › | $10.94M | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
